marcus evans > reviews > press releases
marcus evans press : Latest press releases from around our events & companies

CMIC Co. Ltd - A Win-Win Outcome with CROs


Kazuo Nakamura from CMIC Co., Ltd., a sponsor company at the upcoming marcus evans Evolution Summit 2011 and Evolution Summit 2012, on maximising the CRO-pharmaceutical company relationship.

Interview with: Kazuo Nakamura, Chief Executive Officer, CMIC Co., Ltd.


“The Contract Research Organisation (CRO) is a key part of the development of orphan drugs,” says Kazuo Nakamura, Chief Executive Officer, CMIC Co., Ltd. When the profit margin is low, a CRO developing drugs for pharmaceutical companies results in a win-win outcome for both parties.

From a sponsor company at the upcoming marcus evans Evolution Summit 2011, in Montreux, Switzerland, 17 - 19 October and Evolution Summit 2012, in North America, Nakamura talks about maximising the CRO-pharmaceutical company partnership, and his expectations for the coming years.

What insights do you have into what is challenging Chief Medical Officers (CMOs) of pharmaceutical companies today?

Kazuo Nakamura: Some pharmaceutical companies want to enter the orphan drug development market, yet they do not have the know-how. Licensing out in the Japanese market is complicated and requires expertise and negotiating with local authorities. Many want to sell the drugs without heavily investing into the development themselves. 

The pharmaceutical market in Asia holds great potential, which is why many large companies from across the world are looking into taking advantage of the opportunities the region has to offer. However, they cannot necessarily do it alone. CROs play a key role in this.

Asia is also attractive when it comes to recruiting a vast number of patients for clinical trials; CROs can facilitate and speed up that process.

How can clinical trial safety and efficiency be enhanced?

Kazuo Nakamura: CMIC is challenging the process of innovation in drug development. Conducting clinical trials is at times too complicated, hindering innovation. The government is very conservative and in some cases we have a very big documentation backlog. CMIC is trying to re-engineer this process.

What would help pharmaceutical companies maximise return on investment?

Kazuo Nakamura: Pharmaceutical companies need to form strategic partnerships with their CROs. Old-fashioned type of outsourcing such as using them like one part of their company is no more productive. Developing the new process to facilitate the trial with their partnered CRO is essential to reduce the cost while maintaining the good level of trial quality and data integrity. From this point of view selecting the appropriate CRO and providing them with the information they need would be the key to success in developing the drug sooner. Close collaboration is necessary for a win-win situation.

What are your expectations for the coming years?

Kazuo Nakamura: Lately translational research programs are increasing at the academic centres strongly backed up by the governmental financial support in Japan. These programmes are expected to prove the concept of the programme for future contribution to the patients.

We, CROs, can play an important role to support their R&D in terms of pre-clinical studies and clinical studies for the targeted technologies in compliance with the necessary regulations. CMOs should carefully watch the result of these activities and not lose the opportunity to license-in their technologies.

Sarin Kouyoumdjian-Gurunlian
Press Manager
marcus evans, Summits Division
Tel: + 357 22 849 313

For more information please send an email to or visit the event websites below:

Evolution Summit 2011 - Europe:

Evolution Summit 2012 - North America:

marcus evans group - life sciences /pharma sector portal

Complementing our summit format, the Pharma Network – marcus evans Summits group delivers peer-to-peer information on strategic matters, professional trends and breakthrough innovations. Lend an ear to fellow experts and live news from our events on our LinkedIn and Twitter accounts!



Please note that the summit is a closed business event and the number of participants strictly limited.

About CMIC Co., Ltd

The CMIC Group has been taking the lead in the industry since 1992 when it started the first ever CRO (Contract Research Organization) business in Japan.

Using its abundant experience, CMIC comprehensively supports pharmaceutical companies in carrying out their value chains of drug development, manufacturing and marketing & sales

About marcus evans Summits

marcus evans Summits are high level business forums for the world’s leading decision-makers to meet, learn and discuss strategies and solutions. Held at exclusive locations around the world, these events provide attendees with a unique opportunity to individually tailor their schedules of keynote presentations, think tanks, seminars and one-to-one business meetings. For more information, please visit

All rights reserved. The above content may be republished or reproduced – kindly inform us by sending an email to


We welcome your comments on this article
Job title / full name:

marcus evans group news
Latest Press Releases